136759-41-6

Usage

Uses

Used in Pharmaceutical Industry:
(S)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is used as a key intermediate in the synthesis of various drugs, particularly for the development of antipsychotic and antifungal medications. Its role in inhibiting squalene epoxidase makes it a promising candidate for the treatment of fungal infections.
Used in Antifungal Applications:
In the field of antifungal therapy, (S)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is used as an active ingredient to target and inhibit the enzyme squalene epoxidase. This inhibition disrupts the biosynthesis of ergosterol, an essential component of fungal cell membranes, thereby helping to combat fungal infections.
Used in Anti-Inflammatory and Antioxidant Research:
(S)-6-Methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid is also being studied for its potential anti-inflammatory and antioxidant properties. These characteristics make it a subject of interest in drug development and research, as it may contribute to the creation of new medications for treating inflammation and oxidative stress-related conditions.

InChI:InChI=1/C12H14O3/c1-15-11-5-4-8-6-10(12(13)14)3-2-9(8)7-11/h4-5,7,10H,2-3,6H2,1H3,(H,13,14)/t10-/m0/s1

Upstream product

• 2471-69-4 6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid 
• 16425-80-2 ethyl 6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate 
• 156152-66-8 (1S,2S)-1-Hydroxy-6-methoxy-1,2,3,4-tetrahydro-naphthalene-2-carboxylic acid ethyl ester 

Downstream Products

• 177017-69-5 (S)-6-methoxy-2-aminotetraline 

Relevant academic research and scientific papers

Microbial Reduction of 1-Tetralone 2-Carboxyesters as a Source of New Asymmetric Synthons

The reduction of unsubstituted or methoxy-substituted (+/-)-2-carboxyethyl-1-tetralones by selected microorganisms affords optically active 1-hydroxy-2-carboxyethyl tetralins which can be used as versatile asymmetric synthons, for example in the preparation of biologically active methoxy-substituted 2R-aminotetralins. 1R,2R-(cis)-hydroxyesters of high optical purity are obtained with yeast strains, while the use of filamentous fungi leads to the enantiomeric 1S,2S-(cis)-hydroxyesters.

OXOPYRROLIDINE UREA FPR2 AGONISTS

The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. (I)

Kappa opioid receptor ligands

Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid

Enzymatic process for the preparation of optically active tetralin derivatives

The present invention relates to an enzymatic process for the preparation of optically active tetrahydro-2-naphthoic acids from the corresponding racemic esters by reaction with a lipase.